Status:
COMPLETED
Effects of Escitalopram on the Sleep EEG Power in Patients With Major Depressive Disorder
Lead Sponsor:
Peking University Sixth Hospital
Collaborating Sponsors:
National Institute on Drug Dependence, China
Conditions:
Depressive Disorder, Major
Eligibility:
MALE
22-40 years
Phase:
NA
Brief Summary
The main objective was to compare the differences of PSG parameters and plasma melatonin levels before and after treatment with escitalopram for 8 weeks. Polysomnography (PSG) was detected over a nigh...
Detailed Description
1. Design and participants: The patients with MDD were screened from the hospital, age- and gender-matched healthy controls were recruited by advertising from the community who signed written informed...
Eligibility Criteria
Inclusion
- Clinical diagnosis of MDD;
- Hamilton Rating Scale for Depression 17-items (HRSD-17) total scores ≥ 22;
- Male patients aged between 18 and 45 years
Exclusion
- Significant suicide risk by HRSD suicide scores \> 2;
- Accompanied with psychiatric symptoms;
- Treated with MECT within 6 months.
Key Trial Info
Start Date :
May 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2018
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT04013464
Start Date
May 1 2016
End Date
December 30 2018
Last Update
July 9 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.